Camp4 Therapeutics Corp Income Statement
CAMP|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$3M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$53M
FY2025
Net Income
-$80M
FY2025
Camp4 Therapeutics Corp reported $3M in revenue and $80M in net loss for FY2025. Revenue increased 899.4% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $3.5M | $350.0K |
| SG&A Expense | $17.4M | $11.6M |
| R&D Expense | $38.2M | $40.6M |
| Operating Income | -$52.6M | -$51.9M |
| Income Tax | $0 | $0 |
| Net Income | -$80.4M | -$49.3M |
| EPS (Basic) | -$11.04 | -$124.80 |
| EPS (Diluted) | -$11.04 | -$124.80 |
| Shares Outstanding | 20.1M | 460.7K |
| Operating Margin | -1502.4% | -14822.6% |
| Profit Margin | -2298.5% | -14083.1% |